Clinical Trial Update: Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) [Phase 2]

View source ↗

Summary

Galderma R&D has launched a Phase 2 proof-of-concept study to characterize the pharmacokinetics and pharmacodynamics of nemolizumab in adults with chronic pruri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pruritus of Unknown Origin

Drugs mentioned

• Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Chronic Pruritus of Unknown Origin | Phase 2 | Status: RECRUITING